Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery
NCT ID: NCT00130715
Last Updated: 2015-03-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
INTERVENTIONAL
1998-06-30
2003-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Randomized Control Trial on Seprafilm and Guardix in Preventing Ileus
NCT02168426
Retrospective Acute Care Appendectomy Study
NCT06624215
Small Bowel Obstruction in Virgin Abdomen
NCT06912581
Mechanical Bowel Preparation for Elective Colorectal Anastomosis
NCT02731963
Functional Lumen Opening With Self-Forming Magnetic Anastomosis
NCT06454916
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Seprafilm Bioresorbable Membrane
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients undergoing laparoscopy
* Patients undergoing surgery for treatment of acute abdominal trauma
* Patients with an abscess (abdominal or pelvic) present during the initial surgery
* Patients with a history of pulmonary embolus or deep vein thrombosis (DVT) within 1 year of surgery
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genzyme, a Sanofi Company
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic
Scottsdale, Arizona, United States
Kaiser Permanente Medical Center
Los Angeles, California, United States
USC School of Medicine
Los Angeles, California, United States
Harbor UCLA
Torrence, California, United States
Washington Hospital Center
Washington D.C., District of Columbia, United States
Cleveland Clinic
Weston, Florida, United States
Johns Hopkins Medical Center
Baltimore, Maryland, United States
Boston Medical Center
Boston, Massachusetts, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Mayo Medical Center
Rochester, Minnesota, United States
Colon & Rectal Surgery Associates
Saint Paul, Minnesota, United States
Washington University School of Medicine
St Louis, Missouri, United States
Mount Sinai School of Medicine
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Cleveland Clinic
Cleveland, Ohio, United States
University of Texas Medical School
Houston, Texas, United States
Mount Sinai Hospital
Toronto, Ontario, Canada
University of Erlangen
Erlangen, , Germany
University Hospital Nijmegen
Nijmegan, , Netherlands
University of Hull
Hull, , United Kingdom
St. Mary's Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SF97-0601
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.